Interfant-21 Treatment Protocol for Infants Under 1 Year With KMT2A-rearranged ALL or Mixed Phenotype Acute Leukemia

This study is a treatment protocol with blinatumomab for infants under 1 year old who are diagnosed with acute lymphoblastic leukemia with a specific unfavorable genetic alteration. The purpose of the study is to improve the outcome of this disease in infants.

Trial Details

NCT ID

NCT05327894

Phase

PHASE3

Sponsor

Princess Maxima Center for Pediatric Oncology

Status

RECRUITING

Cancer Type

Leukemia

Interventions

Blinatumomab

Locations (sample)

Buenos Aires, Argentina|-34.61315,-58.37723
Clayton, Victoria, Australia|-37.91667,145.11667
Adelaide, Australia|-34.92866,138.59863
Clayton, Australia|-37.91667,145.11667
New Lambton Heights, Australia|-32.92466,151.69364

Key Eligibility Criteria

Patients with newly diagnosed B- precursor ALL or B-cell MPAL (single lineage) according to the WHO classification of tumours of haematopoietic and…
≤ 365 days of age at the time of diagnosis of ALL.
Written informed consent of the parent(s) or other legally authorized guardian of the patient according to local law and regulations.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →